ReviewThe Prostate2020
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Review in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis.European journal of medical research · 2025Pooled it
- Cardiovascular risks in men with prostate cancer: a pragmatic, clinician-oriented review of risk stratification and management strategies.Prostate cancer and prostatic diseases · 2026Review
- Article
- Article
- Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical.Frontiers in oncology · 2026Article
- Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients.Investigative and clinical urology · 2025Article
- Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway.Future oncology (London, England) · 2025Review
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study.Future oncology (London, England) · 2025Article
- Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment.Translational oncology · 2025Article
- Beyond castration: defining maximal testosterone control in advanced prostate cancer.Frontiers in endocrinology · 2025Article
- Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.The Journal of urology · 2025Article
- Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen-targeted Radioguided Surgery for Oligorecurrent Prostate Cancer.European urology open science · 2024Article
- Article
- Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.Prostate cancer and prostatic diseases · 2024Review
- Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?Translational andrology and urology · 2024Article
- Current Clinical Aspects of Androgen Deprivation Therapy for Locally Advanced and Metastatic Prostate Cancer: A Scoping Review for Urologists and Medical Providers.Research and reports in urology · 2024Article
- Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer.Pharmacological reports : PR · 2023Review
- The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well-described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk-benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review.
methodsA 14-member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings.
resultsThis article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting.
conclusionThe panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate-sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.